1. Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, Compagnino F, Icardi G, Durando P.
Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance
of cross-protection. Vaccine 2009; 27: 3345-3348
2. Arias CF, Escalera-Zamudio M, Soto-Del Rio MD, Cobián-Güemes AG, Isa P, López S.
Molecular anatomy of 2009 influenza virus A (H1N1). Arch Med Res 2009; 40: 643-654
3. Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr Topics Microbiol
Immunol 2009; 333: 323-344
4. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production:
moving towards cell culture-based vaccines. Expert Rev Vaccines 2009; 8: 607-618
5. Boni MF. Vaccination and antigenic drift in influenza. Vaccine 2008; 26S: C8-C14
6. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008; 26S: D49-D53
7. Caillet C, Piras F, Bernard M-C, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste
C, Kusters I. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009
vaccines induce strong antibody responses in seasonal influenza vaccine-primed and
unprimed mice. Vaccine 2010; doi: 10.1016/j.vaccine.2010.02.050
8. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25:
6852-6862
9. Chu D W-S, Hwang S-J, Lim FS, Oh HML, Thongvharoen, Yang P-C, Bock HL, Dramé
M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW, H5N1 Flu Study Group for
Hong kong, Singapore, Taiwan and Thailand. Immunogenicity and tolerability of an
AS03A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population
of Asian adults. Vaccine 2009; 27: 7428-7435
10. Collin N, de Radiguès X, the WHO H1N1 Vaccine Task Force. Vaccine production capacity
for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009; 27: 5184-5186
11. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M,
Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. A phase I trial of a
PER.C6Ò cell grown influenza H7 virus vaccine. Vaccine 2009; 27: 1889-1897
61
12. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine
OptafluÒ (Novartis Vaccines). Expert Rev Vaccines 2009; 8: 679-688
13. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microb
Infect 2010; 12: 280-286
14. Erlich HJ, Müller M, Oh HML, Tambyah PA, Joukhadar C, Montomoli E, Fisher D,
Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrowsky R, Pavlova BG, Pöllabauer
EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team.
A clinical trial of a whole virus H5N1 vaccine derived from cell culture. N Engl J Med
2008; 358: 2573-2584
15. Erlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G,Löw-Baselli A, van der Velden
MVW, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HML, Montomoli E,
Kistner O, Barrett PN. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces
cross-reactive memory responses. J Infect Dis 2009; 200: 1113-1118
16. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Topics Microbiol
Immunol 2009; 333: 43-82
17. Furuse Y, Suzuki A, Kishi M, Nukiwa N, Shimizu M, Sawayama R, Fuji N, Oshitani H.
Occurence of mixed populations of influenza A viruses that can be maintained through
transmission in a single host and potential for reassortment. J Clin Microbiol 2010; 48: 369-
374
18. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol 2009;
45: 174-178
19. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines.
Expert Rev Vaccines 2009; 8: 1681-1692
20. Ghendon Y. Cold-adapted, live influenza vaccines developed in Rusia. In “Nicholson KG,
Webster RG, Hay AJ(Eds): Textbook of Influenza”. Blackwell Science 1998; pp: 391-399
21. He C-Q, Xie Z-X, Han G-Z, Dong J-B, Wang D, Liu J-B, Ma L-Y, Tang X-F, Liu X-P,
Pang Y-S, Li G-R. Homologous recombination as an evolutionary force in the avian
influenza A virus. Mol Biol Evol 2009; 26: 177-187
22. Hensley SE, Yewdell JW. Que sera, sera: evolution of the swine H1N1 influenza A virus.
Expert Rev Anti Infect Ther 2009; 7: 763-768
23. Jennings LC, Monto AS, Chan PKS, Szucs TD, Nicholson KG. Stockpiling prepandemic
influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis
2008; 8: 650-658
24. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney
R, Innis B, Fries L. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted
prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J
Infect Dis 2010; 201: 1644-1653
25. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster
J-M, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted
62
rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007;
370: 580-589
26. Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic
influenza vaccine development. Expert Rev Vaccines 2009; 8: 401-423
27. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn A-D, Vandermeulen C, Forgus S,
Leroux-Roels G, Pichon S, Kusters I. An adjuvanted, low-dose, pandemic influenza A
(H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune
responses in healty adults. J Infect Dis 2008; 198: 642-649
28. Liang X-F, Wang H-Q, Wang J-Z, Fang H-H, Wu J, Zhu F-C, Li R-C, Xia S-L, Zhao Y-L,
Li F-J, Yan S-H, Yin W-D, An K, Feng D-J, Cui X-L, Qi F-C, Ju C-J, Zhang Y-H, Guo ZJ,
Chen P-Y, Chen Z, Yan K-M, Wang Y. Safety and immunogenecity of 2009 pandemic
influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebocontrolled
trial. Lancet 2010; 375: 56-66
29. Lin T, Wang G, Li A, Zhang Q, Wu C, Zhang R, Cai Q, Song W, Yuen K-Y. The
hemagglutinin structure of an avian H1N1 influenza A virus. Virology 2009; 392: 73-81
30. Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts
or fiction? Eur J Intern Med 2010; 21: 70-73
31. Minor PD. Vaccines against seasonal and pandemic influenza and the implications of
changes in substrates for virus production. Clin Infect Dis 2010; 50: 560-565
32. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens
JGM, Kino Y, Kistner O, Kompier R, Makizumi K, Medema J, Mimori S, Ryan D, Schwartz
R, Smith JSB, Sugawara K, Trusheim H, Tsai TF, Krause R. Current challenges in
implementing cell-derived influenza vaccines: implications for production and regulation,
July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27: 2907-2913
33. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev
Vaccines 2009; 8: 383-389
34. Morens DM, Taubenberger JK, Harvey HA, Memoli MJ. The 1918 influenza pandemic:
lessons for 2009 and the future. Crit Care Med 2010; 38[Suppl.]: e10-e20
35. O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against
influenza virus infection. Expert Rev Vaccines 2007; 6: 699-710
36. O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – ‘the long and
winding road’. Drug Discov Today 2009; 14: 541-551
37. Patridge J, kieny MP, World health Organization H1N1 influenza vaccine Task Force.
Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and
comparison with previous estimates and global action plan targets. Vaccine 2010;
doi:10.1016/j.vaccine.2010.04.083
38. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin
Microbiol Rev 2007; 20: 243-267
63
39. Pellegrini M, Nicolay U, Lindert K, Groth N, Cioppa GD. MF59-adjuvanted versus nonadjuvanted
influenza vaccines: integrated analysis from a large safety database. Vaccine
2009; 27: 6959-6965
40. Prieto-Lara E, Llanos-Méndez A. Safety and immunogenicity of prepandemic H5N1
influenza vaccines: a systematic review of the literature. Vaccine 2010; 28: 4328-4334
41. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza
vaccines. Vaccine 2008; 26S: D41-D44
42. Russel CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, Gust ID, Hampson AW,
Hay AJ, Hurt AC, de Jong JC, Kelso A, Klimov AI, Kageyama T, Komadina N, Lapedes
AS, Lin YP, Mosterin A, Obuchi M, Odagiri T, Osterhause ADME, Rimmelzwaan GF,
Shaw MW, Skepner E, Stohr K, Tashiro M, Fouchier RAM, Smith DJ. Influenza vaccine
strain selection and recent studies on the global migration of seasonal influenza viruses.
Vaccine 2008; 26S: D31-D34
43. Settembre EC, Dormitzer PR, Rappuoli R. H1N1: can a pandemic cycle be broken? Sci
Transl Med 2010; 2: 24ps14
44. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, SebastianR, Chong M, Tam
T, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza
using a sentinel physician network: Results from the 2005-2006 season of dual A and B
vaccine mismatch in Canada. Vaccine 2007; 25: 2842-2851
45. Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against Pandemic
influenza. Immunity 2006; 24: 5-9
46. Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: From surveillance through
production to protection. Mayo Clin Proc 2010; 85: 257-273
47. Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted
influenza vaccines during pregnancy – a retrospective analysis. Vaccine 2010; 28: 1877-
1880
48. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza
vaccines. Expert Rev Vaccines 2009; 8: 483- 492
49. Wang C-C, Chen J-R, Tseng Y-C, Hsu C-H, Hung Y-F, Chen S-W, Chen C-M, Khoo K-H
Cheng T-J, Cheng Y-SE, Jan J-T, Wu C-Y, Ma C, Wong C-H. Glycans on influenza
hemagglutinin affect receptor binding and immune response. PNAS 2009; 106: 18137-
18142
50. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannamüehler MJ,
Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci
2009; 98: 1278-1316.
Thank you for copying data from http://www.arastirmax.com
